Holen Sie sich die Stockscreener-App
1.27
0.78%
-0.01
Schlusskurs vom Vortag:
$1.28
Offen:
$1.28
24-Stunden-Volumen:
77,165
Relative Volume:
0.06
Marktkapitalisierung:
$2.88M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.44M
KGV:
-1.6835
EPS:
-0.7544
Netto-Cashflow:
$-28.30M
1W Leistung:
-18.06%
1M Leistung:
-31.72%
6M Leistung:
-63.19%
1J Leistung:
-87.61%
1-Tages-Spanne:
$1.25
$1.29
1-Wochen-Bereich:
$1.25
$1.5894
52-Wochen-Spanne:
$1.25
$19.41
Nucana Plc Adr Stock (NCNA) Company Profile
Vergleichen Sie NCNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| NCNA | 1.28 | 2.88M | 0 | -33.44M | -28.30M | -0.7544 |
| VRTX | 449.64 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.66 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.13 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.50 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-03-03 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-10-22 | Eingeleitet | Truist | Buy |
| 2020-07-24 | Eingeleitet | Oppenheimer | Outperform |
| 2019-08-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-10-23 | Eingeleitet | Citigroup | Buy |
| 2017-10-23 | Eingeleitet | Jefferies | Buy |
| 2017-10-23 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Nucana Plc Adr Aktie (NCNA) Neueste Nachrichten
Trading Day Triumph: NuCana plc ADR (NCNA) Ends at 2.45, a -10.91 Surge/Plunge - The Dwinnex
Get in on NuCana plc ADR’s (NCNA) buy-in window today! - SETE News
NuCana plc ADR Inc. (NCNA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
NCNA’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
NuCana secures new US patent for cancer treatment NUC-7738 - Investing.com India
Market Watch: NuCana plc ADR (NCNA)’s Noteworthy Drop, Closing at 3.05 - The Dwinnex
Daily Market Movement: NuCana plc ADR (NCNA) Sees a -7.03 Decrease, Closing at 3.44 - The Dwinnex
William Blair downgrades NuCana plc ADR (NCNA) rating to a Mkt perform - Knox Daily
There is no doubt that NuCana plc ADR (NCNA) ticks all the boxes. - SETE News
Wolfspeed Inc [WOLF] Investment Appeal on the Rise - Knox Daily
Labcorp Holdings Inc. (LH) may enjoy gains as insiders got busy in the recent days - Knox Daily
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
NCNA’s Financial Health: Exploring NuCana plc ADR’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
Analyzing NCNA’s price-to-book ratio for the last quarter - US Post News
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September - Benzinga
Endava PLC Sponsored ADR (DAVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Opera Limited Sponsored ADR (OPRA) Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance
Did Jim Cramer Say Buy Arm Holdings PLC – ADR (NASDAQ:ARM) Industrial Stock Before Rate Cuts? - Yahoo Finance
NuCana price target lowered to $25 from $150 at Oppenheimer - TipRanks
In the Green: NuCana plc ADR (NCNA) Closes at 3.66, Up/Down -52.65 from Previous Day - The Dwinnex
NuCana stock downgraded by William Blair after halted cancer study - Investing.com India
NuCana halts NuTide:323 study on colorectal cancer - Investing.com
NuCana Ends Phase 2 Cancer Study, Focuses on Promising Treatments - TipRanks
Check out these key findings about NuCana plc ADR (NCNA) - SETE News
NCNA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update - The Bakersfield Californian
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
Sea Limited Sponsored ADR (SE) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
XPeng Inc. Sponsored ADR (XPEV) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Co-Diagnostics (CODX) to Post Q2 Earnings: What's in Store? - Yahoo Canada Shine On
NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag - Yahoo Singapore News
NuCana Stops Patient Enrollment in Pancreatic Cancer Study - Yahoo Sport Australia
Citi Appointed as Successor Depositary Bank for Iberdrola, S.A.’s ADR Programme - Yahoo Finance
NuCana to Participate in the 2022 Jefferies Healthcare Conference - The Globe and Mail
NuCana to Present at the Jefferies Virtual London Healthcare Conference - The Globe and Mail
Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC - Yahoo Lifestyle UK
Analysts Estimate Endava PLC Sponsored ADR (DAVA) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session - Yahoo New Zealand News
Should You Buy NuCana (NCNA) Ahead of Earnings? - Yahoo News UK
Should You Buy ARM Holdings (ARM) Ahead of Earnings? - Yahoo Finance
NuCana plc Announces Reverse ADS Split - TipRanks
Why Sea Limited Sponsored ADR (SE) Might be Well Poised for a Surge - Yahoo Finance
Why Opera Limited Sponsored ADR (OPRA) Outpaced the Stock Market Today - Yahoo Finance
NuCana: Potential Turnaround In 2024 But Risky - Seeking Alpha
Davion Enters into Agreement with The Bank of New York Mellon for ADR Programme and $30 Million IPO Fundraise - Yahoo Finance
Bears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' Now - Yahoo Finance
MARKET DATA - The Wall Street Journal
Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA) - Yahoo Finance
The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit - Yahoo Finance
NuCana Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters ... - The Globe and Mail
Finanzdaten der Nucana Plc Adr-Aktie (NCNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):